

Joana Paredes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2910367/publications.pdf>

Version: 2024-02-01

86
papers

4,945
citations

76326

40
h-index

95266

68
g-index

88
all docs

88
docs citations

88
times ranked

7312
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 453-464.	2.9	2
2	Breast Cancer Stem Cell Membrane Biomarkers: Therapy Targeting and Clinical Implications. <i>Cells</i> , 2022, 11, 934.	4.1	11
3	<i>Cadherin</i> is a novel oncogenic biomarker with prognostic value in glioblastoma. <i>Molecular Oncology</i> , 2022, 16, 2611-2631.	4.6	4
4	Epithelial-Mesenchymal Plasticity Induced by Discontinuous Exposure to TGF β 1 Promotes Tumour Growth. <i>Biology</i> , 2022, 11, 1046.	2.8	3
5	Sympathetic activity in breast cancer and metastasis: partners in crime. <i>Bone Research</i> , 2021, 9, 9.	11.4	29
6	Cadherin Expression and EMT: A Focus on Gliomas. <i>Biomedicines</i> , 2021, 9, 1328.	3.2	30
7	The Chick Chorioallantoic Membrane Model: A New In Vivo Tool to Evaluate Breast Cancer Stem Cell Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 334.	4.1	18
8	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology</i> , The, 2020, 21, e386-e397.	10.7	237
9	BR-BCSC Signature: The Cancer Stem Cell Profile Enriched in Brain Metastases that Predicts a Worse Prognosis in Lymph Node-Positive Breast Cancer. <i>Cells</i> , 2020, 9, 2442.	4.1	10
10	P-cadherin induces anoikis-resistance of matrix-detached breast cancer cells by promoting pentose phosphate pathway and decreasing oxidative stress. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165964.	3.8	19
11	Expression of PD-L1 in primary breast carcinoma and lymph node metastases. <i>Surgical and Experimental Pathology</i> , 2019, 2, .	0.6	14
12	Clinical spectrum and pleiotropic nature of <i>CDH1</i> germline mutations. <i>Journal of Medical Genetics</i> , 2019, 56, 199-208.	3.2	74
13	Heterogeneity and Plasticity of Breast Cancer Stem Cells. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 83-103.	1.6	42
14	Evaluation of AAV-mediated delivery of shRNA to target basal-like breast cancer genetic vulnerabilities. <i>Journal of Biotechnology</i> , 2019, 300, 70-77.	3.8	16
15	The Crosstalk Between Cell Adhesion and Cancer Metabolism. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1933.	4.1	67
16	Pan-cancer association of a centrosome amplification gene expression signature with genomic alterations and clinical outcome. <i>PLoS Computational Biology</i> , 2019, 15, e1006832.	3.2	35
17	S100P is a molecular determinant of E-cadherin function in gastric cancer. <i>Cell Communication and Signaling</i> , 2019, 17, 155.	6.5	16
18	Mobile Magnetic Nanocatalysts for Bioorthogonal Targeted Cancer Therapy. <i>Advanced Functional Materials</i> , 2018, 28, 1705920.	14.9	92

#	ARTICLE	IF	CITATIONS
19	Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation. <i>Nature Communications</i> , 2018, 9, 1258.	12.8	113
20	SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells. <i>Cell Communication and Signaling</i> , 2018, 16, 75.	6.5	14
21	Geometric compensation applied to image analysis of cell populations with morphological variability: a new role for a classical concept. <i>Scientific Reports</i> , 2018, 8, 10266.	3.3	6
22	Dependence of Tensional Homeostasis on Cell Type and on Cell-Cell Interactions. <i>Cellular and Molecular Bioengineering</i> , 2018, 11, 175-184.	2.1	16
23	P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice. <i>Modern Pathology</i> , 2017, 30, 698-709.	5.5	18
24	Actin stress fiber organization promotes cell stiffening and proliferation of pre-invasive breast cancer cells. <i>Nature Communications</i> , 2017, 8, 15237.	12.8	132
25	Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. <i>Journal of Clinical Pathology</i> , 2017, 70, 860-867.	2.0	47
26	Capturing quantitative features of protein expression from in situ fluorescence microscopic images of cancer cell populations. , 2017, , 279-297.		0
27	Quantification of topological features in cell meshes to explore E-cadherin dysfunction. <i>Scientific Reports</i> , 2016, 6, 25101.	3.3	16
28	Atomic force microscopy and graph analysis to study the P-cadherin/SFK mechanotransduction signalling in breast cancer cells. <i>Nanoscale</i> , 2016, 8, 19390-19401.	5.6	18
29	Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation. <i>Scientific Reports</i> , 2016, 6, 34860.	3.3	26
30	P-cadherin and the journey to cancer metastasis. <i>Molecular Cancer</i> , 2015, 14, 178.	19.2	113
31	OXPHOS dysfunction regulates integrin- α 1 modifications and enhances cell motility and migration. <i>Human Molecular Genetics</i> , 2015, 24, 1977-1990.	2.9	35
32	Targeting lactate transport suppresses <i>in vivo</i> breast tumour growth. <i>Oncotarget</i> , 2015, 6, 19177-19189.	1.8	92
33	The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. <i>BMC Cancer</i> , 2014, 14, 734.	2.6	25
34	High-throughput molecular profiling of a P-cadherin overexpressing breast cancer model reveals new targets for the anti-cancer bacterial protein azurin. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 50, 1-9.	2.8	22
35	Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. <i>Endocrine-Related Cancer</i> , 2014, 21, 27-38.	3.1	54
36	P-Cadherin Linking Breast Cancer Stem Cells and Invasion: A Promising Marker to Identify an "Intermediate/Metastable"-EMT State. <i>Frontiers in Oncology</i> , 2014, 4, 371.	2.8	87

#	ARTICLE	IF	CITATIONS
37	P-cadherin signals through the laminin receptor $\alpha 6 \beta 4$ integrin to induce stem cell and invasive properties in basal-like breast cancer cells. <i>Oncotarget</i> , 2014, 5, 679-692.	1.8	49
38	Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. <i>Journal of Clinical Pathology</i> , 2013, 66, 187-191.	2.0	132
39	P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. <i>Journal of Pathology</i> , 2013, 229, 705-718.	4.5	68
40	Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. <i>Human Molecular Genetics</i> , 2013, 22, 84-95.	2.9	44
41	Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: Key events in the progression from an in situ to an invasive breast carcinoma. <i>Cell Cycle</i> , 2013, 12, 2684-2690.	2.6	36
42	CCAAT/Enhancer Binding Protein β (C/EBP β) Isoforms as Transcriptional Regulators of the Pro-Invasive CDH3/P-Cadherin Gene in Human Breast Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e55749.	2.5	20
43	The Bacterial Protein Azurin Impairs Invasion and FAK/Src Signaling in P-Cadherin-Overexpressing Breast Cancer Cell Models. <i>PLoS ONE</i> , 2013, 8, e69023.	2.5	30
44	CLMP Is Essential for Intestinal Development, but Does Not Play a Key Role in Cellular Processes Involved in Intestinal Epithelial Development. <i>PLoS ONE</i> , 2013, 8, e54649.	2.5	17
45	Vitamin D and the mammary gland: a review on its role in normal development and breast cancer. <i>Breast Cancer Research</i> , 2012, 14, 211.	5.0	55
46	E-cadherin dysfunction in gastric cancer - Cellular consequences, clinical applications and open questions. <i>FEBS Letters</i> , 2012, 586, 2981-2989.	2.8	74
47	<i>CPEB1</i> , a novel gene silenced in gastric cancer: a <i>Drosophila</i> approach. <i>Gut</i> , 2012, 61, 1115-1123.	12.1	41
48	CLMP Is Required for Intestinal Development, and Loss-of-Function Mutations Cause Congenital Short-Bowel Syndrome. <i>Gastroenterology</i> , 2012, 142, 453-462.e3.	1.3	49
49	P-cadherin Is Coexpressed with CD44 and CD49f and Mediates Stem Cell Properties in Basal-like Breast Cancer. <i>Stem Cells</i> , 2012, 30, 854-864.	3.2	64
50	Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 545-553.	2.8	22
51	Epithelial E- and P-cadherins: Role and clinical significance in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 297-311.	7.4	137
52	Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. <i>Breast</i> , 2012, 21, 354-360.	2.2	43
53	1 α ,25-dihydroxyvitamin D ₃ induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. <i>Anticancer Research</i> , 2012, 32, 249-57.	1.1	63
54	Claudin expression in breast cancer: high or low, what to expect?. <i>Histology and Histopathology</i> , 2012, 27, 1283-95.	0.7	18

#	ARTICLE	IF	CITATIONS
55	Bacterial protein azurin as a new candidate drug to treat untreatable breast cancers. , 2011, , .		3
56	Identification of the Gene Underlying Congenital Short Bowel Syndrome, Pointing to Its Major Role in Intestinal Development. <i>Gastroenterology</i> , 2011, 140, S-89.	1.3	0
57	Oncogenic mutations in gastric cancer with microsatellite instability. <i>European Journal of Cancer</i> , 2011, 47, 443-451.	2.8	92
58	Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. <i>Journal of Clinical Pathology</i> , 2011, 64, 937-946.	2.0	483
59	Molecular phenotypes of matched in situ and invasive components of breast carcinomas. <i>Human Pathology</i> , 2011, 42, 1438-1446.	2.0	10
60	P-cadherin role in normal breast development and cancer. <i>International Journal of Developmental Biology</i> , 2011, 55, 811-822.	0.6	64
61	Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions. <i>BMC Cancer</i> , 2010, 10, 483.	2.6	164
62	Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. <i>Histopathology</i> , 2010, 56, 860-867.	2.9	168
63	Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. <i>Oncogene</i> , 2010, 29, 392-402.	5.9	106
64	Co-expression of E- and P-cadherin in breast cancer: role as an invasion suppressor or as an invasion promoter?. <i>BMC Proceedings</i> , 2010, 4, .	1.6	1
65	ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBP α in CDH3 gene activation. <i>Human Molecular Genetics</i> , 2010, 19, 2554-2566.	2.9	18
66	Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. <i>Human Molecular Genetics</i> , 2010, 19, 697-706.	2.9	26
67	P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. <i>Histology and Histopathology</i> , 2010, 25, 963-74.	0.7	46
68	The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. <i>Human Molecular Genetics</i> , 2009, 18, 2599-2608.	2.9	100
69	Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. <i>Breast Cancer Research</i> , 2009, 11, R40.	5.0	134
70	Expression of E-cadherin, P-cadherin and β -catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. <i>Veterinary Journal</i> , 2008, 177, 45-53.	1.7	54
71	Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. <i>Journal of Clinical Pathology</i> , 2008, 61, 856-862.	2.0	60
72	Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. <i>European Journal of Surgical Oncology</i> , 2007, 33, 1061-1067.	1.0	40

#	ARTICLE	IF	CITATIONS
73	P-cadherin expression in breast cancer: a review. <i>Breast Cancer Research</i> , 2007, 9, 214.	5.0	93
74	Expression of p120-Catenin Isoforms Correlates with Genomic and Transcriptional Phenotype of Breast Cancer Cell Lines. <i>Analytical Cellular Pathology</i> , 2007, 29, 467-476.	1.4	14
75	P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 73-80.	2.8	71
76	P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based cytology. <i>Cytopathology</i> , 2005, 16, 88-93.	0.7	11
77	P-Cadherin Promotes Cell-Cell Adhesion and Counteracts Invasion in Human Melanoma. <i>Cancer Research</i> , 2005, 65, 8774-8783.	0.9	87
78	P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation. <i>Clinical Cancer Research</i> , 2005, 11, 5869-5877.	7.0	236
79	P-Cadherin Is Up-Regulated by the Antiestrogen ICI 182,780 and Promotes Invasion of Human Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 8309-8317.	0.9	70
80	P-Cadherin Expression in Canine Mammary Tissues. <i>Journal of Comparative Pathology</i> , 2004, 130, 13-20.	0.4	22
81	Novel and Classic Myoepithelial/Stem Cell Markers in Metaplastic Carcinomas of the Breast. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2003, 11, 1-8.	1.2	99
82	Title is missing!. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 2003, 11, 1-8.	2.0	32
83	Evaluation of breast cancer metastases in pleural effusions by molecular biology techniques. <i>Diagnostic Cytopathology</i> , 2002, 27, 210-213.	1.0	17
84	P-cadherin expression in canine lactating mammary gland. <i>Journal of Cellular Biochemistry</i> , 2002, 86, 420-421.	2.6	9
85	P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 16-21.	2.8	63
86	Aberrant P-Cadherin Expression: Is it Associated with Estrogen-Independent Growth in Breast Cancer?. <i>Pathology Research and Practice</i> , 2002, 198, 795-801.	2.3	34